Mar 13, 2025 | Business Cases, Oncology

RESILIENCE | RC-102 | Oncology | IC DM

PRAISE (Patient-Reported AutoImmunity Secondary to Cancer immunothErapy) is a real-life longitudinal observational study aiming to identify autoimmune manifestations in patients treated with immune checkpoint inhibitors, either as monotherapy or in combination therapy.

 

Study started in November 2019, with estimated end date in November 2025.

 

Enrollment was completed in early 2023 with 905 patients included.

 

Role of Alsinova: design, planning, and full-service execution of an e-cohort of 900 oncology patients (physician, patient, SNDS, and biobank).